Fang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fang Li has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chuan-Yuan Li
Chinese Institute for Molecular and Cellular Therapeutics, Chinese Institutes for Medical Research, Beijing, China
19 shared publications - Dong Pan
Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
19 shared publications - Meng Jiao
Department of Dermatology, Duke University Medical Center, Durham, North Carolina
19 shared publications - Mengjie Hu
Department of Dermatology, Duke University Medical Center, Durham, North Carolina
19 shared publications - Jinming Yu
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
10 shared publications - Yanyan Zhu
Chinese Institute for Molecular and Cellular Therapeuitcs, Chinese Institutes for Medical Research, Beijing, China
10 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary figures and tables
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary figures and tables
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Radiotherapy (RT) is commonly used to try to eliminate any remaining tumor cells following surgical resection of glioma. However, tumor recurrence is prevalent, highlighting the unmet medical need to develop therapeutic strategies to enhance the efficacy of RT in glioma. Focusing on the radiosensitizing potential of the currently approved drugs known to cross the blood-brain barrier can facilitate rapid clinical translation. Here, we assessed the role of catechol-O-methyltransferase (COMT), a key enzyme to degrade catecholamines and a drug target for Parkinson’s disease, in glioma treatment. Analysis of The Cancer Genome Atlas data showed significantly higher COMT expression levels in both low-grade glioma and glioblastoma compared to normal brain tissues. Inhibition of COMT by genetic knockout or FDA-approved COMT inhibitors significantly sensitized glioma cells to RT in vitro and in vivo. Mechanistically, COMT inhibition in glioma cells led to mitochondria dysfunction and increased mitochondrial RNA release into the cytoplasm, activating the cellular antiviral double-stranded RNA sensing pathway and type I interferon (IFN) response. Elevated type I IFNs stimulated the phagocytic capacity of microglial cells, enhancing RT efficacy. Given the long-established safety record of the COMT inhibitors, these findings provide a solid rationale to evaluate them in combination with RT in patients with glioma.Significance:Inhibition of catechol-O-methyltransferase, a well-established drug target in Parkinson’s disease, interferes with mitochondrial electron transport and induces mitochondrial double-stranded RNA leakage, activating type I interferon signaling and sensitizing glioma to radiotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Radiotherapy (RT) is commonly used to try to eliminate any remaining tumor cells following surgical resection of glioma. However, tumor recurrence is prevalent, highlighting the unmet medical need to develop therapeutic strategies to enhance the efficacy of RT in glioma. Focusing on the radiosensitizing potential of the currently approved drugs known to cross the blood-brain barrier can facilitate rapid clinical translation. Here, we assessed the role of catechol-O-methyltransferase (COMT), a key enzyme to degrade catecholamines and a drug target for Parkinson’s disease, in glioma treatment. Analysis of The Cancer Genome Atlas data showed significantly higher COMT expression levels in both low-grade glioma and glioblastoma compared to normal brain tissues. Inhibition of COMT by genetic knockout or FDA-approved COMT inhibitors significantly sensitized glioma cells to RT in vitro and in vivo. Mechanistically, COMT inhibition in glioma cells led to mitochondria dysfunction and increased mitochondrial RNA release into the cytoplasm, activating the cellular antiviral double-stranded RNA sensing pathway and type I interferon (IFN) response. Elevated type I IFNs stimulated the phagocytic capacity of microglial cells, enhancing RT efficacy. Given the long-established safety record of the COMT inhibitors, these findings provide a solid rationale to evaluate them in combination with RT in patients with glioma.Significance:Inhibition of catechol-O-methyltransferase, a well-established drug target in Parkinson’s disease, interferes with mitochondrial electron transport and induces mitochondrial double-stranded RNA leakage, activating type I interferon signaling and sensitizing glioma to radiotherapy.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Additional data on DGAT1 deficiency-induced tumor ferroptosis.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Additional data on DGAT1 deficiency-induced tumor ferroptosis.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Additional data from ScRNA-seq analysis of intratumoral CD45+ cells in DGAT1-deficient B16F10 tumors.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Additional data from ScRNA-seq analysis of intratumoral CD45+ cells in DGAT1-deficient B16F10 tumors.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
SgRNA sequences used to knockout the DGAT1 gene.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
SgRNA sequences used to knockout the DGAT1 gene.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Additional data on lipid droplet reduction-induced lipid peroxidation and mitochondrial dysfunction in DGAT1-deficient cells.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Additional data on lipid droplet reduction-induced lipid peroxidation and mitochondrial dysfunction in DGAT1-deficient cells.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Ferroptosis, a form of regulated cell death driven by lipid peroxidation, has emerged as a promising mechanism in cancer therapy. However, the lack of clinically viable ferroptosis inducers has precluded its therapeutic evaluation in patients. In this study, we demonstrated that inhibition of diacylglycerol O-acyltransferase 1 (DGAT1) induces a ferroptosis-like phenotype in cancer cells and enhances the efficacy of immune checkpoint blockade (ICB) therapy. In human cancer cohorts, low DGAT1 expression correlated with improved prognosis and elevated ferroptosis-associated gene signatures. In murine models, both genetic knockout and pharmacologic inhibition of DGAT1 enhanced ICB therapy efficacy by promoting increased infiltration of cytotoxic T lymphocytes. Mechanistically, DGAT1 inhibition reduced lipid droplet accumulation, triggering elevated lipid peroxidation, mitochondrial dysfunction, and reactive oxygen species production. These events culminated in glutathione peroxidase 4 depletion and ferroptosis. Given the availability of clinical-stage DGAT1 inhibitors, these findings provide a strong rationale for repurposing these agents as ferroptosis inducers to improve responses to cancer immunotherapy.Significance:DGAT1 inhibition promotes ferroptosis by reducing lipid droplet accumulation, increasing lipid peroxidation, and inducing mitochondrial dysfunction, ultimately enhancing sensitivity to immune checkpoint blockade and offering a promising strategy for improving cancer treatment.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Ferroptosis, a form of regulated cell death driven by lipid peroxidation, has emerged as a promising mechanism in cancer therapy. However, the lack of clinically viable ferroptosis inducers has precluded its therapeutic evaluation in patients. In this study, we demonstrated that inhibition of diacylglycerol O-acyltransferase 1 (DGAT1) induces a ferroptosis-like phenotype in cancer cells and enhances the efficacy of immune checkpoint blockade (ICB) therapy. In human cancer cohorts, low DGAT1 expression correlated with improved prognosis and elevated ferroptosis-associated gene signatures. In murine models, both genetic knockout and pharmacologic inhibition of DGAT1 enhanced ICB therapy efficacy by promoting increased infiltration of cytotoxic T lymphocytes. Mechanistically, DGAT1 inhibition reduced lipid droplet accumulation, triggering elevated lipid peroxidation, mitochondrial dysfunction, and reactive oxygen species production. These events culminated in glutathione peroxidase 4 depletion and ferroptosis. Given the availability of clinical-stage DGAT1 inhibitors, these findings provide a strong rationale for repurposing these agents as ferroptosis inducers to improve responses to cancer immunotherapy.Significance:DGAT1 inhibition promotes ferroptosis by reducing lipid droplet accumulation, increasing lipid peroxidation, and inducing mitochondrial dysfunction, ultimately enhancing sensitivity to immune checkpoint blockade and offering a promising strategy for improving cancer treatment.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Analysis of PD-L1 levels in TCGA and DGAT1 inhibited samples
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy
Analysis of PD-L1 levels in TCGA and DGAT1 inhibited samples